30 Years of Healthy Energy For All Skin
Continuing to Engineer the Future of Aesthetic Medicine
(1996-2005)
The Science Comes First
We chose to be right, not first.
The laser industry had a skin tone problem. We spent nearly a decade solving it - engineering 650-micropulse pulse technology that made safe treatments across all Fitzpatrick skin types possible for the first time.
• 1996
Aerolase founded with a singular misson: create laser technology safe for all skin types.
• 2000
First FDA 510(k) clearance - validation without compromise.
• 2004
Expanded FDA clearances established LightPod Neo and LightPod Era platforms for future innovations.
• 2005
Clinical foundation complete, medical advisory board established.
Nine years. Zero shortcuts. The science was proven before commercial pressure ever entered the equation.
We expanded geographically before we expanded commercially.
We didn't chase volume — we chose our first customers as carefully as we'd chosen our technology. Clinical outcomes, not marketing budgets, drove adoption.
• 2006–2010
Controlled US market entry with industry leading dermatologists adopting the technology and conducting case studies.
• 2011–2012
International distributors came to us — drawn by clinical results, not sales pitches.
• 2013–2014
Technology refined based on global feedback across diverse patient populations.
• 2015–2016
Foundation for structured international expansion in place.
Every adoption was intentional. Every case study was a proof point.
(2006-2015)
Proving It Works Everywhere
(2016-2025)
Building the Engine to Scale
From technology pioneer to market leader.
The science was undeniable. Now we built the commercial engine to match it.
• 2017
First major European expansion. CE Mark obtained.
• 2018
Neo Elite and Era Elite launch. Commercial infrastructure begins.
• 2021
First dedicated North America marketing and clinical teams. Aerolase Mexico formalized.
• 2022
Major sales expansion across North America, Exci308 added to the Aerolase technology portfolio, Business plan to target Dermatologists, Plastic Surgeons, and Aestheticians.
• 2023
Australia market development, expanded KOL network across all specialties.
• 2024
Matured sales infrastructure and market segmentation, formalized customer success programs.
• 2025
Hybrid Fractional Era launched, Aerolase India established, Era Focus in development.
Proving what 30 years of precision enables.
Three decades of physics-first innovation. One unwavering commitment: healthy energy that works for every patient, every time.
The Next 30 Years
We're not just celebrating where we've been. We're defining where the industry is going!
(2026+)
The Confidence Era
Three Decades of Impact
3000+
Practices served.
1M
Patients treated.
25+
Countries reached.
I-VI
Skin Types Safely Treated.
"For a long time, we’ve looked for devices that were safe and effective for a variety of skintones. For patients that have darker skin that are looking for hair removal, rejuvenation, treatment of blood vessels, bruises, we didn’t really have that device until Aerolase came along. It’s safe and effective and I can use it on any patient.”
